CA2828595C - Utilisation de tetraamines chelatant le cuivre destines au traitement de maladies cardiovasculaires et d'insuffisance cardiaque - Google Patents
Utilisation de tetraamines chelatant le cuivre destines au traitement de maladies cardiovasculaires et d'insuffisance cardiaque Download PDFInfo
- Publication number
- CA2828595C CA2828595C CA2828595A CA2828595A CA2828595C CA 2828595 C CA2828595 C CA 2828595C CA 2828595 A CA2828595 A CA 2828595A CA 2828595 A CA2828595 A CA 2828595A CA 2828595 C CA2828595 C CA 2828595C
- Authority
- CA
- Canada
- Prior art keywords
- copper
- patient
- diabetic
- diabetes
- trientine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Une méthode damélioration de la réparation de tissu endommagé de tissu chez un patient mammalien à partir de celui du myocarde, de larbre vasculaire et des organes qui dépendent de larbre vasculaire, ladite méthode comprenant ou intégrant létape de donner au patient, ou dadministrer au patient, un agent ou des agents efficaces pour réduire les valeurs de cuivre du corps du patient à une teneur suffisante pour améliorer la réparation des tissus.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2982327A CA2982327A1 (fr) | 2002-03-08 | 2003-03-10 | Utilisation de tetraamines chelatant le cuivre destines au traitement de maladies cardiovasculaires et d'insuffisance cardiaque |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ517721 | 2002-03-08 | ||
NZ51772102 | 2002-03-08 | ||
NZ51772502 | 2002-03-11 | ||
NZ517725 | 2002-03-11 | ||
US36438202P | 2002-03-12 | 2002-03-12 | |
US60/364,382 | 2002-03-12 | ||
CA2478997A CA2478997C (fr) | 2002-03-08 | 2003-03-10 | Utilisation de tetraamines chelatant le cuivre destines au traitement de maladies cardiovasculaires et d'insuffisance cardiaque |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2478997A Division CA2478997C (fr) | 2002-03-08 | 2003-03-10 | Utilisation de tetraamines chelatant le cuivre destines au traitement de maladies cardiovasculaires et d'insuffisance cardiaque |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2982327A Division CA2982327A1 (fr) | 2002-03-08 | 2003-03-10 | Utilisation de tetraamines chelatant le cuivre destines au traitement de maladies cardiovasculaires et d'insuffisance cardiaque |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2828595A1 CA2828595A1 (fr) | 2003-09-25 |
CA2828595C true CA2828595C (fr) | 2017-11-28 |
Family
ID=46801737
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2828595A Expired - Fee Related CA2828595C (fr) | 2002-03-08 | 2003-03-10 | Utilisation de tetraamines chelatant le cuivre destines au traitement de maladies cardiovasculaires et d'insuffisance cardiaque |
CA2982327A Abandoned CA2982327A1 (fr) | 2002-03-08 | 2003-03-10 | Utilisation de tetraamines chelatant le cuivre destines au traitement de maladies cardiovasculaires et d'insuffisance cardiaque |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2982327A Abandoned CA2982327A1 (fr) | 2002-03-08 | 2003-03-10 | Utilisation de tetraamines chelatant le cuivre destines au traitement de maladies cardiovasculaires et d'insuffisance cardiaque |
Country Status (3)
Country | Link |
---|---|
CA (2) | CA2828595C (fr) |
ES (1) | ES2642633T3 (fr) |
PT (2) | PT1487431E (fr) |
-
2003
- 2003-03-10 PT PT03744567T patent/PT1487431E/pt unknown
- 2003-03-10 CA CA2828595A patent/CA2828595C/fr not_active Expired - Fee Related
- 2003-03-10 CA CA2982327A patent/CA2982327A1/fr not_active Abandoned
- 2003-03-10 ES ES11187394.9T patent/ES2642633T3/es not_active Expired - Lifetime
- 2003-03-10 PT PT111873949T patent/PT2500018T/pt unknown
Also Published As
Publication number | Publication date |
---|---|
CA2982327A1 (fr) | 2003-09-25 |
ES2642633T3 (es) | 2017-11-17 |
CA2828595A1 (fr) | 2003-09-25 |
PT1487431E (pt) | 2012-08-02 |
PT2500018T (pt) | 2017-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2478997C (fr) | Utilisation de tetraamines chelatant le cuivre destines au traitement de maladies cardiovasculaires et d'insuffisance cardiaque | |
JP2005533003A5 (fr) | ||
WO2004017957A1 (fr) | Prevention et/ou traitement de maladies cardio-vasculaires et/ou insuffisance cardiaque associee | |
WO2003075910A1 (fr) | Prevention et/ou traitement d'une maladie vasculaire, d'une cardiomyopathie et/ou d'une defaillance cardiaque associee | |
Huebschmann et al. | Diabetes and advanced glycoxidation end products | |
Hoffman et al. | Myocardial reperfusion injury: etiology, mechanisms, and therapies | |
Tan et al. | AGE, RAGE, and ROS in diabetic nephropathy | |
Folli et al. | The role of oxidative stress in the pathogenesis of type 2 diabetes mellitus micro-and macrovascular complications: avenues for a mechanistic-based therapeutic approach | |
Son | Reactive oxygen and nitrogen species in pathogenesis of vascular complications of diabetes | |
Monnier | Intervention against the Maillard reaction in vivo | |
Kishi et al. | Oxidative stress and the role of redox signalling in chronic kidney disease | |
Adler et al. | Impaired regulation of renal oxygen consumption in spontaneously hypertensive rats | |
US7652037B2 (en) | Methods of lowering lipid levels in a mammal | |
US20030060490A1 (en) | Method for the treatment and prevention of urinary stone disease | |
Tsutsui et al. | Oxidative stress in cardiac and skeletal muscle dysfunction associated with diabetes mellitus | |
Yan et al. | Iron accumulation and lipid peroxidation: implication of ferroptosis in diabetic cardiomyopathy | |
CA2828595C (fr) | Utilisation de tetraamines chelatant le cuivre destines au traitement de maladies cardiovasculaires et d'insuffisance cardiaque | |
NZ545724A (en) | Use of a copper chelator for preventing and/or treating cardiovascular disease and/or associated heart failure | |
Antonopoulos et al. | Novel therapeutic strategies targeting vascular redox in human atherosclerosis | |
US8580854B2 (en) | Methods of suppression of rage gene expression and rage triggered inflammatory genes by selected age-inhibitors | |
Alvarez et al. | Impact of advanced glycation end products on endothelial function and their potential link to atherosclerosis | |
Schalkwijk | Therapeutic interventions in the glyc (oxid) ation pathway | |
Lima et al. | Research Article Curcumin, Alone or in Combination with Aminoguanidine, Increases Antioxidant Defenses and Glycation Product Detoxification in Streptozotocin-Diabetic Rats: A Therapeutic Strategy to Mitigate Glycoxidative Stress | |
Coughlan et al. | Can you reduce your AGE?: Strategies to prevent AGE accumulation in diabetes | |
Liao et al. | New Approach to Preventing and Treating Diabetes Mellitus: Focus on Advanced Glycation End Products (AGE) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20131001 |
|
MKLA | Lapsed |
Effective date: 20210310 |